Outpatient Pharmacogenomic Screenings to Prevent Addiction, Overdose, and Suicide.

ABSTRACT: Point-of-care genetic testing for single nucleotide polymorphisms (SNPs) to improve psychiatric treatment in outpatient settings remains a challenge. The presence or absence of certain genomic alleles determines the activity of the encoded enzymes, which ultimately defines the individual's drug metabolism rate. Classification of poor metabolizers (PMs) and rapid/ultrarapid metabolizers (RMs/UMs) would facilitate personalization and precision of treatment. However, current pharmacogenomic (PGx) testing of multiple genes is comprehensive and requires quantitative analyses for interpretations. We recommend qualitative, fast-track, point-of-care screenings, which are one- or-two gene-based analyses, as a quick initial screening tool to potentially eliminate the need for an expensive quantitati

SUBMITTER: Yarlagadda A 

PROVIDER: S-EPMC10773601 | biostudies-literature | 2023 Oct-Dec

REPOSITORIES: biostudies-literature